
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus is leveraging its strong clinical data from the NEST and UNICORN trials to prioritize the initiation of the Phase 3 ROBBIN trial in the neoadjuvant setting for MSS-CRC patients, supported by a shift in resources to this program as well as a $340M private placement. With a potential early filing for approval based on the interim analysis, milestone payments from ongoing collaborations, and a ~5 year patent extension for bot/bal, Agenus is well-positioned to capitalize on the potential of its promising immunotherapy assets.
Bears say
Agenus is currently projected to have a difficult time achieving their $25 price target in the long-term, as their discounted cash flow analysis projects a negative terminal value and relies on relatively conservative assumptions for their leading product candidates. In addition, risks to the achievement of the price target include potential safety concerns, lower-than-expected efficacy in clinical trials, commercial competition, changes to programs and regulations, financing requirements, and potential issues with intellectual property protection.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares